Shandong University of Traditional Chinese Medicine (SDUTCM; simplified Chinese: 山东中医药大学; traditional Chinese: 山東中醫藥大學; pinyin: Shān dōngzhōngyī yàodà xué) is a university based in Jinan City, Shandong Province, China.
Introduction and aims South Asia bears the heaviest burden of other pharyngeal cancers in Asia, including cancers of the oropharynx (International Classification of Diseases, Tenth Revision: C09-C10) and hypopharynx (International Classification of Diseases, Tenth Revision: C12-C13), yet systematic analyses remain limited. This study quantifies the evolving burden and attributable risks of other pharyngeal cancers in the region. Methods Using data from the Global Burden of Disease Study 2023 (GBD 2023), this secondary analysis assessed age- and sex-specific other pharyngeal cancer burden and risk-attributable burden in South Asia from 1990 to 2023. Temporal trends were assessed using joinpoint regression, and age-period-cohort modelling was used to characterize age, period, and cohort patterns. Results In 2023, GBD 2023 estimated 81,600 new other pharyngeal cancer cases, 61,400 deaths, and 1.91 million DALYs in South Asia. The region had the highest estimated age-standardized rates in Asia, and Bangladesh had the highest burden within South Asia. After 2015, marked increases in age-standardized incidence, mortality, and DALY rates were estimated in South Asia. While the burden was concentrated among middle-aged and older males, the 15 to 49 age group had the fastest estimated growth. The 1994 birth cohort had an estimated incidence rate ratio of 2.11 relative to the 1949 reference cohort. Smoking and chewing tobacco accounted for the largest proportions of risk-attributable burden among males and females, respectively. Since 2019, the burden attributable to the assessed risk factors has increased sharply. Conclusion GBD 2023 estimates indicate that South Asia had the highest burden of other pharyngeal cancers in Asia, with increasing trends and major attributable burdens from smoking and chewing tobacco. Clinical relevance These findings may inform other pharyngeal cancer prevention, tobacco/alcohol risk reduction, dental public health planning, and regional health-policy planning in South Asia.
Hypoxia is a feature of the tumor microenvironment (TME), which is closely associated with tumor invasion and drug resistance. It has been confirmed that alleviating tumor hypoxia is a crucial strategy for enhancing the tumor treatment efficacy. With the development of nanomedicine, stimulus-responsive nanomedicine delivery systems (NDDS) with the ability to reshape the TME have attracted significant attention. These NDDS typically consist of stimulus-responsive frameworks and cargo. They remain stable under normal physiological conditions and release their cargo only upon specific stimuli, such as acidic pH or high GSH levels. In addition to stimuli in the TME, numerous external stimuli have been used to activate the NDDS in recent years, such as thermal, near-infrared light and ultrasound. Unlike previous reviews, we integrate internal and external stimulus-responsive strategies with hypoxia-alleviating mechanisms to guide the rational design of novel nanosystems. Furthermore, we highlight emerging multi-stimulus-responsive platforms, with particular emphasis on their potential for precise control and clinical translation.
Therapeutic resistance remains a major cause of treatment failure and disease recurrence across cancer types, considerably limiting the long-term efficacy of chemotherapies, targeted therapies, and immunotherapies. Growing evidence indicates that resistance cannot be fully explained by static genetic alterations but rather arises from dynamic and reversible adaptive processes. Epigenetic regulation governs transcriptional plasticity, cellular state transitions, and tumor heterogeneity under therapeutic stress. Alterations in DNA methylation, histone modifications, chromatin accessibility, and non-coding RNA networks enable cancer cells to silence tumor suppressor programs, activate compensatory survival pathways, acquire stem cell-like drug-tolerant persister states, and remodel the tumor immune microenvironment. These mechanisms often act in a coordinated manner to form a dynamic regulatory system that supports adaptive resistance. However, current studies have frequently focused on individual epigenetic regulators and have lacked an integrated framework to explain how epigenetic plasticity collectively drives therapeutic resistance. In this review, we deconstruct cancer therapy resistance using the conceptual framework of the “epigenetic landscape.” We summarize the molecular functions and crosstalk among the major epigenetic layers and describe how this integrated network sustains key resistance-associated phenotypes. We also discuss emerging therapeutic strategies that target epigenetic plasticity, including epigenetic drugs, targeted protein degradation, epigenetic editing, and rational combination therapies. Overall, this review provides a systematic framework for understanding epigenetically mediated therapy resistance and highlights epigenetic plasticity as a therapeutic vulnerability for developing durable cancer treatments.
Metabolic diseases (MetDs), characterized by metabolic dysregulation leading to abnormal blood glucose, lipid, and uric acid levels, frequently result in organ damage, functional impairment, and multiple complications. These conditions severely compromise quality of life and increase mortality risk, constituting a major global health burden. Icariin (ICA), a major bioactive compound derived from Epimedium species, has demonstrated substantial therapeutic potential in the management of MetD. Accumulating evidence indicates that ICA exerts beneficial effects by improving insulin resistance and modulating oxidative stress, fibrosis, inflammatory responses, and lipid metabolism. Through these mechanisms, ICA influences the pathogenesis and progression of diabetes mellitus, osteoporosis, metabolic dysfunction–associated steatotic liver disease, obesity, and various metabolic disorders. This review provides a comprehensive summary of recent advances in the application of ICA for the management of MetD, focusing on its molecular mechanisms, clinical applications, and research prospects. The aim is to establish a solid foundation for optimizing the therapeutic use of ICA in the management of MetDs.
Idiopathic pulmonary fibrosis (IPF) represents a chronic, non-reversible, and irreversible interstitial lung disease with the lack of curative interventions and a poor prognosis; identifying safe and effective therapeutic agents is of paramount importance. The Ophiopogon-Ginseng herb pair, a classical traditional Chinese medicine (TCM), exerts Qi-replenishing and Yin-nourishing effects. Its active constituents Ophiopogonin D (OP-D), Ginsenoside Rg1 (Rg1), and Ginsenoside Rg3 (Rg3) have individual anti-fibrotic potential, while their synergistic effects in IPF remain to be elucidated. This study aimed to explore how OP-D-Rg1-Rg3 attenuates IPF and to clarify its possible molecular mechanisms. Bleomycin (BLM)-induced cellular senescence and transforming growth factor-β1 (TGF-β1) induce epithelial-mesenchymal transition (EMT) in A549 cells. MTT assay and RSM determined the optimal combination ratio. Cellular senescence and EMT were assessed by SA-β-Gal staining, RT-qPCR, WB, and ELISA. An IPF mouse model was established by intratracheal BLM administration, followed by treatment with the optimized OP-D-Rg1-Rg3 combination, pirfenidone (PFD), or saline for 21 days. Pulmonary structural alterations and molecular changes were then evaluated by micro-CT, HE, Masson, and molecular analyses. The results showed that the synergistic OP-D-Rg1-Rg3 combination markedly attenuated A549 cell senescence, as evidenced by reduced SA-β-Gal activity and decreased expression of p53, p21, p16, and TGF-β1-induced EMT (upregulated E-cadherin, downregulated vimentin, fibronectin, Col-I). In vivo, the combination alleviated AEC2s senescence and pulmonary EMT, improved mouse body weight and lung morphology, reduced histopathological damage, and attenuated IPF. In conclusion, the OP-D-Rg1-Rg3 combination ameliorates IPF by inhibiting AEC2s senescence and EMT, highlighting promising clinical application prospects for IPF treatment.